Sostieni la Ricerca

Pubblicazioni scientifiche – estratto aggiornato al 4 novembre 2017

da | Nov 4, 2017 | News, Pubblicazioni

Sternberg CN et al. Randomized Phase III Trial of High Dose Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) Chemotherapy and Recombinant Human Granulocyte Colony Stimulating Factor Versus Classic M-VAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 2001;19(10):2638-2646.

continua su   Pubmed   –  Ascopubs

Sternberg CN et al for the EORTC Genito-Urinary Cancer Group. Seven Year Update of an EORTC Phase III Trial of High-Dose Intensity M-VAC Chemotherapy and G-CSF Versus Classic M-VAC in Advanced Urothelial Tract Tumours. Eur J Cancer 2006 Jan;42(1):50-4.

continua su   Pubmed   –   EJCancer

Sternberg CN et al for the SPARC Study Group. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients with Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy. The SPARC Trial. J Clin Oncol 2009 Nov 10; 27(32):5431-5438.

continua su   Pubmed   –   Ascopubs

Sternberg CN et al. Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010 Feb 20; 28(6):1061-1068.

continua su   Pubmed   –   Ascopubs

Sternberg CN et al. Improved Outcomes in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer Treated with The Androgen Receptor Inhibitor Enzalutamide: Results From The Phase 3 AFFIRM Trial. Ann Oncol 2014; 25:429-434.

continua su   Pubmed   –   Annals of Oncology

Sternberg CN et al for Abiraterone Global EAP Investigators. Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Chemotherapy: Final Analysis of a Multicentre, Open-Label, Early-Access Protocol Trial. Lancet Oncol 2014 Oct;15(11):1263-8.

continua su   Pubmed   –   The Lancet Oncology

Sternberg CN et al for the EORTC. Immediate Versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial. Lancet Oncol 2015 Jan;16(1):76-86.

continua su   Pubmed   –   The Lancet Oncology

Sternberg C et al. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer. J Clin Oncol 2016 Aug;34(22):2636-2651.

continua su   Pubmed   –   Ascopubs

Motzer RJ, Haas N, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lyun Lee J, Melichar B, Rini B, Choueiri TK, Zemanova M, Wood L, Neil Reaume M, Stenzl A, Chowdhury S, Yeong Lim H, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Paul Russo and Sternberg CN for the PROTECT Investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol 2017 Sep 13. [Epub ahead of print]

continua su   Pubmed   –   Ascopubs

Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, Baneyx G, Banerjee H, Aimone P, and Motzer RJ. Relationships between Pazopanib Exposure and Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clin Cancer Res 2017 (submitted).